Dolutegravir (DTG)
Dolutegravir is an integrase strand transfer inhibitor (INSTI) that blocks the action of integrase, an HIV enzyme. This prevents the virus from multiplying and reduces the viral load in the body.
Dosage by Body Weight
Can be taken with or without food. Dispersible tablets should be dissolved in water and not swallowed whole, chewed, or crushed. Standard adult dose is 50 mg once daily, or twice daily if co-administered with certain CYP3A/UGT1A inducers.
- Body Weight
- Below 5 kg
- Dose
- 5 mg
- Frequency
- Once daily
- Tracking Notes
- Approved for infants weighing at least 3 kg and at least 4 weeks of age. Administered using 10 mg dispersible tablets (half a tablet).
- Body Weight
- 5-7 kg
- Dose
- 5 mg to 15 mg
- Frequency
- Once daily
- Tracking Notes
- 5 mg once daily for 3 to <6 kg. 15 mg once daily for 6 to <10 kg, using 10 mg dispersible tablets.
- Body Weight
- 8-10 kg
- Dose
- 15 mg
- Frequency
- Once daily
- Tracking Notes
- Administered using 10 mg dispersible tablets (1.5 tablets once daily).
- Body Weight
- 11-15 kg
- Dose
- 20 mg to 25 mg
- Frequency
- Once daily
- Tracking Notes
- 20 mg (2 dispersible tablets) once daily for 10 to <14 kg. 25 mg (2.5 dispersible tablets) once daily for 14 to <20 kg.
- Body Weight
- 16-20 kg
- Dose
- 25 mg
- Frequency
- Once daily
- Tracking Notes
- Administered using 10 mg dispersible tablets (2.5 tablets once daily).
| Body Weight | Dose | Frequency | Tracking Notes |
|---|---|---|---|
| Below 5 kg | 5 mg | Once daily | Approved for infants weighing at least 3 kg and at least 4 weeks of age. Administered using 10 mg dispersible tablets (half a tablet). |
| 5-7 kg | 5 mg to 15 mg | Once daily | 5 mg once daily for 3 to <6 kg. 15 mg once daily for 6 to <10 kg, using 10 mg dispersible tablets. |
| 8-10 kg | 15 mg | Once daily | Administered using 10 mg dispersible tablets (1.5 tablets once daily). |
| 11-15 kg | 20 mg to 25 mg | Once daily | 20 mg (2 dispersible tablets) once daily for 10 to <14 kg. 25 mg (2.5 dispersible tablets) once daily for 14 to <20 kg. |
| 16-20 kg | 25 mg | Once daily | Administered using 10 mg dispersible tablets (2.5 tablets once daily). |
Formulation
Purpose
Used in combination with other antiretroviral medicines for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults and pediatric patients.
Generic Name
DolutegravirBranded Drug Names
Dolutegravir (DTG) is listed as a generic drug name. Common branded medicines that may contain the same active ingredient include:
Scheduled Drug
Yes. This medicine should be supplied or used only according to applicable prescription and regulatory requirements.